Novo Nordisk Other Non-Current Liabilities 2010-2024 | NVO

Novo Nordisk other non-current liabilities for the quarter ending June 30, 2024 were $1.089B, a 25.84% increase year-over-year.

  • Novo Nordisk other non-current liabilities for 2023 were $0.993B, a 49.51% increase from 2022.
  • Novo Nordisk other non-current liabilities for 2022 were $0.664B, a 11.83% decline from 2021.
  • Novo Nordisk other non-current liabilities for 2021 were $0.753B, a 8.62% increase from 2020.

Novo Nordisk Other Non-Current Liabilities 2010-2024 | NVO

  • Novo Nordisk other non-current liabilities for 2023 were $0.993B, a 49.51% increase from 2022.
  • Novo Nordisk other non-current liabilities for 2022 were $0.664B, a 11.83% decline from 2021.
  • Novo Nordisk other non-current liabilities for 2021 were $0.753B, a 8.62% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$495.1B
Johnson & Johnson (JNJ)$450.1B
Merck (MRK)$270B
AbbVie (ABBV)$264.1B
AstraZeneca (AZN)$218.5B
Novartis AG (NVS)$218.4B
Pfizer (PFE)$201.2B
Sanofi (SNY)$133B
Innoviva (INVA)$953M